Login
Registrati
Reimposta password
Pubblica & Distribuisci
Soluzioni Editoriali
Soluzioni di Distribuzione
Temi
Architettura e design
Arti
Business e Economia
Chimica
Chimica industriale
Farmacia
Filosofia
Fisica
Geoscienze
Ingegneria
Interesse generale
Legge
Letteratura
Linguistica e semiotica
Matematica
Medicina
Musica
Scienze bibliotecarie e dell'informazione, studi library
Scienze dei materiali
Scienze della vita
Scienze informatiche
Scienze sociali
Sport e tempo libero
Storia
Studi classici e del Vicino Oriente antico
Studi culturali
Studi ebraici
Teologia e religione
Pubblicazioni
Riviste
Libri
Atti
Editori
Blog
Contatti
Cerca
EUR
USD
GBP
Italiano
English
Deutsch
Polski
Español
Français
Italiano
Carrello
Home
Riviste
Pneumologia
Volume 69 (2020): Numero 2 (December 2020)
Accesso libero
Systemic inflammation, TNM staging and survival in patients with lung cancer
Ionela Erhan
Ionela Erhan
,
Stefan Dumitrache-Rujinski
Stefan Dumitrache-Rujinski
,
Claudia Toma
Claudia Toma
e
Miron Bogdan
Miron Bogdan
| 31 dic 2020
Pneumologia
Volume 69 (2020): Numero 2 (December 2020)
INFORMAZIONI SU QUESTO ARTICOLO
Articolo precedente
Articolo Successivo
Sommario
Articolo
Immagini e tabelle
Bibliografia
Autori
Articoli in questo Numero
Anteprima
PDF
Cita
CONDIVIDI
Article Category:
Original Papers
Pubblicato online:
31 dic 2020
Pagine:
81 - 86
DOI:
https://doi.org/10.2478/pneum-2020-0016
Parole chiave
lung cancer
,
systemic inflammation
,
neutrophil-to-lymphocyte ratio
,
platelet-to-lymphocyte ratio
© 2020 Ionela Erhan et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Figure 1
Difference between NLR, PLR and ESR values in resectable versus nonresectable stages.
Figure 2
Differences in NLR, PLR and ESR values in the two subsets (deceased and surviving patients) of Group A (resectable stages of lung cancer).
Figure 3
Differences in NLR, PLR and ESR values in the two subsets (deceased and surviving patients) of Group B (nonresectable stages of lung cancer).
The value of NLR, PLR and ESR in the two subsets of Group A (n=31) and Group B (n=71)
NLR
PLR
ESR (mm/h)
Subset As (survivors, n=11)
2,36
(0,87–8.36)
138,82
(21,61–416,66)
15
(6–110)
Subset Ad (deceased, n=20)
2,77
(1,25–12,94)
132,57
(41,11–371,17)
62
(11–135)
Subset Bs (survivors, n=8)
1,40
(1,32–1,73)
112,89
(91,14–140,54)
31
(9–90)
Subset Bd (deceased, n=63)
3,59
(0,70–26,60)
183,50
(3,38–651,25)
44
(3–120)
Characteristic of the patients with resectable (Group A) and nonresectable (Group B) lung cancer
102 patients
Age (years)
History of smoking (No, %)
PA (No)
Ne (/mm
3
)
Ly (/mm
3
)
PI (/mm
3
)
NLR
PLR
ESR (mm/h)
Group A (resectable stages) 31 (23 men)
65
(51–83)
23
74,2%
40
(3–100)
6380
(2600-22.000)
2000
(1020-13.600)
294.000
(111.000–709.000)
2,74
(0,87–12,94)
133,95
(21,61–416,66)
35
(6–135)
Group B (nonresectable stages) 71 (63 men)
67
(37–88)
60
84,5%
40
(4–90)
6450
(1800–27.892)
1800
(500–15.700)
327.000
(23.000–661.000)
3,51
(0,76–25,60)
170,37
(3.38–651,25)
40
(3–120)